Introduction
Atrial tachyarrhythmias (ATs) are very common and atrial fibrillation (AF) is the most common sustained arrhythmia. Many patients with ATs have no symptoms during episodes, and subclinical atrial fibrillation (SCAF) is 12-fold more frequent than symptomatic AF in patients with paroxysmal AF (1) . Moreover, both clinical AF and SCAF are associated with an increased risk of thromboembolism. Unfortunately, in many patients, SCAF can only be detected after an ischemic stroke.
Although various cardiac monitoring methods were developed to detect subclinical arrhythmias, guidelines do not address in detail the management of SCAF. The European Heart Rhythm Association recently published a consensus document that addresses the clinical importance, implications, and management of device-detected subclinical ATs with representation from the Heart Rhythm Society, Asia-Pacific Heart Rhythm Society, and Sociedad Latino Americana de Estimulacion Cardiaca y Electrofisiologia (2) . This paper comprehensively reviews the diagnostic tools to detect subclinical atrial arrhythmias and discusses the pathophysiologic link between device-detected SCAF and stroke. It includes answers to many daily clinical questions on the detection of SCAF and treatment with oral anticoagulants.
Detection of subclinical ATs
The consensus document emphasizes the advantage of cardiac electronic devices in detecting SCAF. In particular, patients with cardiac implanted electronic devices (CIEDs) have an advantage over patients who do not receive continuous arrhythmia monitoring because clinically silent arrhythmias can be detected. In addition, remote monitoring can also provide earlier detection compared with the standard scheduled follow-up.
However, even in automatic detection of AF by devices, falsepositive and -negative detections may lead to the misinterpretation of stored data. Therefore, a bipolar atrial lead is crucial for reliable AF detection, and high atrial sensitivity is necessary to avoid intermittent undersensing of AF that can result in an inappropriate detection of persistent AF as multiple short episodes. Most importantly, review of stored intracardiac electrograms to confirm diagnosis and exclude artifacts or reduce the effect of oversensing/undersensing by automated algorithms is recommended by the document.
It is obvious that longer monitoring periods are associated with a greater rate of SCAF detection. Therefore, Holter monitor-ing may be considered for detection of SCAF in high-risk patients with no CIEDs.
The 24-h Holter monitor is the most established but least sensitive device for continuous ECG monitoring. On the other hand, various technologies that provide continuous recording (e.g., longer term Holter monitoring and event recorders) yield a higher detection rate but are more expensive.
Implantable loop recorders are invasive systems. They provide a very long monitoring period, which may be used for AF detection. However, early initiation and interruption of anticoagulation based on remotely detected ATs does not prevent thromboembolism and bleeding (3). We need to wait and see the results of the ongoing studies.
Hand-held electrocardiogram devices are offered as inexpensive and noninvasive tools for screening of SCAFs, particularly in patients with ischemic stroke or TIA without a history of AF.
Device-detected ATs and thromboembolic risk All major studies regarding the thromboembolic risk of SCAF in patients with CIEDs show significant increases in stroke rate associated with device-detected atrial high-rate episodes (AHRE) (4-10). However, the minimum duration of episode or AT/ AF burden (longest total duration of AF on any given day), which confers increased thromboembolic risk, is not precisely defined. In all of these studies, the AF threshold cut-points were either arbitrarily chosen or were the results of the data itself (i.e., median values). Thus, the minimum duration of device-detected AF that increases thromboembolic risk is not certain; it may be as brief as 5 min to several hours.
Another confusing finding is the lack of a distinct temporal association between device-detected atrial arrhythmias and the occurrence of stroke. Related studies revealed unexpected findings: there was no AF on the device recordings in the majority of patients (73%-94%) in the 30 days prior to the thromboembolic events (3, (10) (11) (12) . The lack of distinct temporal association between AHRE and the actual event suggests that the mechanism of stroke is not related to the AF episodes. AHRE could simply be a risk marker for stroke or reflect an indirect mechanism related to multiple comorbidities associated with stroke.
Interestingly, excessive supraventricular ectopic activity is also associated with a risk of incident AF, stroke, and mortality in selected populations depending on the frequency of ectopic beats on Holter (13, 14) . The authors also note that excessive supraventricular ectopic activities documented by Holter monitoring can be considered to be a surrogate marker for paroxysmal AF.
Following a comprehensive discussion, authors ask four important questions and highlight the gaps regarding the relation between device-detected atrial arrhythmias and stroke.
1-Pathophysiologic link between AHRE and stroke is not clear. Are subclinical tachyarrhythmias the cause or just a marker of increased stroke risk?
2-Is there a threshold of tachyarrhythmia duration leading to an elevated stroke risk?
3-Can oral anticoagulation reduce stroke risk in patients with SCAF?
4-Do usual schemes for stroke risk stratification (e.g., CHA 2 DS 2 -VASc) in this setting work equally well as in patients with overt AF?
Device-detected ATs and oral anticoagulation Despite several uncertainties, the consensus report makes valuable recommendations for daily practice, particularly for oral anticoagulation therapy. Recommendations for treatment of SCAF with oral anticoagulation are as follows:
-For patients with two additional CHA 2 DS 2 -VASc risk factors (i.e., ≥2 in males and ≥3 in females), oral anticoagulation is recommended for AF burden >5.5 h/day. Lower duration may merit oral anticoagulation if multiple risk factors are present.
-It is important to recognize that the risk is similarly increased by a mere 5-min episode, but it is reasonable to follow-up a patient with only a single 5-min episode to observe their AF burden over time before committing them to life-long oral anticoagulation.
-Consider oral anticoagulation for AF burden of >5.5 h in patients with one additional CHA 2 DS 2 -VASc risk factor (i.e., score = 1 in males or 2 in females).
-Consider no antithrombotic therapy for any patient with CHA 2 DS 2 -VASc score of 0 in males or 1 in females irrespective of AHRE.
-The presence or absence of symptoms has no bearing on determining the need for anticoagulation.
Conclusion
Silent atrial arrhythmias are becoming more visible with the developing technology and widespread use of cardiac devices. We believe that this document and ongoing studies will guide those who deal with cardiac devices and arrhythmias.
